Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study

BACKGROUND: There is an urgent need to identify biomarkers to guide personalized therapy in castration-resistant prostate cancer (CRPC). We aimed to clinically qualify androgen receptor (AR) gene status measurement in plasma DNA using multiplex droplet digital PCR (ddPCR) in pre- and post-chemothera...

Descripción completa

Detalles Bibliográficos
Autores principales: Conteduca, V., Wetterskog, D., Sharabiani, M. T. A., Grande, E., Fernandez-Perez, M. P., Jayaram, A., Salvi, S., Castellano, D., Romanel, A., Lolli, C., Casadio, V., Gurioli, G., Amadori, D., Font, A., Vazquez-Estevez, S., González del Alba, A., Mellado, B., Fernandez-Calvo, O., Méndez-Vidal, M. J., Climent, M. A., Duran, I., Gallardo, E., Rodriguez, A., Santander, C., Sáez, M. I., Puente, J., Gasi Tandefelt, D., Wingate, A., Dearnaley, D., Demichelis, F., De Giorgi, U., Gonzalez-Billalabeitia, E., Attard, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834043/
https://www.ncbi.nlm.nih.gov/pubmed/28472366
http://dx.doi.org/10.1093/annonc/mdx155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834043/
https://www.ncbi.nlm.nih.gov/pubmed/28472366
http://dx.doi.org/10.1093/annonc/mdx155

Ejemplares similares